Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

NCT07389174 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

mHSPC
mHNPC
Prostate Cancer Adenocarcinoma

Interventions

DRUG: Standard Endocrine Therapy
DIETARY_SUPPLEMENT: LC-K76

Sponsor

Shanghai Changzheng Hospital